This study is looking at how well and how safely povetacicept works for people with primary membranous nephropathy (pMN), a kidney disease. Researchers will compare povetacicept, given as a shot under the skin, with tacrolimus, taken as capsules by mouth. You might be able to join if you are between 18 and 75 years old and have a confirmed diagnosis of pMN. The main goal is to see how many participants achieve a complete clinical remission (CR1) after 104 weeks. The study is currently recruiting about 176 participants, but its status is unclear.

Study design

This interventional study plans to enroll 176 participants. It is evaluating two different treatments: povetacicept and tacrolimus.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint is measured at Week 104, suggesting participants will be followed for at least this duration.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.